Second Alzheimer's Drug Donanemab Faces NHS Use Block

The Alzheimer's drug Donanemab is expected to face a block for its use within the NHS, according to a report by The Telegraph. This marks the second time such a drug has faced obstacles within the UK healthcare system.

The Alzheimer's drug Donanemab is expected to face restrictions from National Health Service (NHS) usage, The Telegraph reports.

This development follows a series of similar barriers faced by Alzheimer's treatments within the UK healthcare framework.

The decision is likely to spark debates about drug accessibility and NHS policy parameters.